# US 2001/0018057 A1 · Mycobacterium vaccae for down-regulation of the Th2 activity of the immune system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0018057 A1
- Document ID: US20010018057A1
- Status: Published application
- Kind: A1
- Application number: 09/761,762
- Filed: 2001-01-18
- Published: 2001-08-30
- Earliest claimed: 1996-12-18
- Assignees: Stanford Rook Limited
- Inventors: Graham A. Rook; John L. Stanford; Alimuddin L. Zumla
- Web page: https://patentgrep.com/patent/US20010018057A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 39/04: Mycobacterium, e.g. Mycobacterium tuberculosis
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/58: {raising an immune response against a target which is not the antigen used for immunisation}
- Y10S 435/863: Mycobacterium
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

Antigenic and/or immunogenic material derived from Mycobacterium vaccae is used to down-regulate Th2 activity of the immune system without up-regulation of Th1 activity. Disorders such as Chronic Fatigue Syndrome, Gulf War Syndrome and Total Allergy Syndrome are treated. The material preferably comprises dead M. vaccae cells in a composition which does not include a non-M. vaccae antigen, immunogen or allergen.

## Claims

### Claim 1

Use of antigenic and/or immunoregulatory material derived from Mycobacterium vaccae in the manufacture of a medicament, which medicament does not include any non-M. vaccae antigen, immunogen or allergen, for treatment of Chronic Fatigue Syndrome by down-regulation of Th2 activity of the immune system of an individual without up-regulation of Th1 activitv of the individual's immune system.

### Claim 2 (depends on 1)

Use according to claim 1 wherein the antigenic and/or immunoregulatory material derived from M. vaccae comprises dead cells of M. vaccae.

### Claim 3 (depends on 2)

Use according to claim 2 wherein the cells have been killed by autoclaving.

### Claim 4

A composition comprising antigenic and/or immunoregulatory material derived from Mycobacterium vaccae and not any non-M. vaccae antigen, immunogen or allergen, for use in treatment or Chronic Fatigue Syndrome by down-regulation of Th2 activity of the immune system of an individual without up-regulation of Th1 activity of the individual's immune system.

### Claim 5 (depends on 4)

A composition according to claim 4 wherein the antigenic and/or immunoregulatory material derived from M. vaccae comprises dead cells of M. vaccae.

### Claim 6 (depends on 5)

A composition according to claim 5 wherein the cells have been killed by autoclaving.

### Claim 7

A method of treating Chronic Fatigue Syndrome by down-regulating Th2 activity of the immune system of an individual without up-regulation of Th1 activity of the individual's immune system, the method comprising administering to the individual a composition comprising antigenic and/or immunoregulatory material derived from Mycobacterium vaccae and not any non-M. vaccae antigen, immunogen or allergen.

### Claim 8 (depends on 7)

A method according to claim 7 wherein the antigenic and/or immunoregulatory material derived from M. vaccae comprises dead cells of M. vaccae.

### Claim 9 (depends on 8)

A method according to claim 8 wherein the cells have been killed by autoclaving.
